Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Ricks, Tiffany K.
162  Ergebnisse:
Personensuche X
?
1

An FDA oncology analysis of toxicities associated with PBD-..:

Saber, Haleh ; Simpson, Natalie ; Ricks, Tiffany K..
Regulatory Toxicology and Pharmacology.  107 (2019)  - p. 104429 , 2019
Link: https://doi.org/10.1016/..
 
?
2

An FDA oncology analysis of CD3 bispecific constructs and f..:

Saber, Haleh ; Del Valle, Pedro ; Ricks, Tiffany K..
Regulatory Toxicology and Pharmacology.  90 (2017)  - p. 144-152 , 2017
Link: https://doi.org/10.1016/..
 
?
3

Successes and Challenges of PARP Inhibitors in Cancer Thera..:

Ricks, Tiffany K. ; Chiu, Haw-Jyh ; Ison, Gwynn...
Frontiers in Oncology.  5 (2015)  - p. , 2015
Link: https://doi.org/10.3389/..
 
?
4

Autoreactive IgE Is Prevalent in Systemic Lupus Erythematos..:

Dema, Barbara ; Pellefigues, Christophe ; Hasni, Sarfaraz...
PLoS ONE.  9 (2014)  2 - p. e90424 , 2014
Link: https://doi.org/10.1371/..
 
?
5

Kinetic Scaffolding Mediated by a Phospholipase C-β and GqS..:

Waldo, Gary L. ; Ricks, Tiffany K. ; Hicks, Stephanie N....
Science.  330 (2010)  6006 - p. 974-980 , 2010
Link: https://www.jstor.org/st..
 
?
6

Kinetic Scaffolding Mediated by a Phospholipase C–β and GqS..:

Waldo, Gary L. ; Ricks, Tiffany K. ; Hicks, Stephanie N....
Science.  330 (2010)  6006 - p. 974-980 , 2010
Link: https://doi.org/10.1126/..
 
?
7

Phosphorylation of Protease-activated Receptor-2 Differenti..:

Ricks, Tiffany K. ; Trejo, JoAnn
Journal of Biological Chemistry.  284 (2009)  49 - p. 34444-34457 , 2009
Link: https://doi.org/10.1074/..
 
?
8

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan..:

Fallah, Jaleh ; Agrawal, Sundeep ; Gittleman, Haley...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159870/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
9

FDA Approval Summary: Margetuximab plus chemotherapy for ad..:

Royce, Melanie ; Osgood, Christy L ; Amatya, Anup K...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012688/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
10

FDA Approval Summary: Belzutifan for von Hippel-Lindau dise..:

Fallah, Jaleh ; Brave, Michael H ; Weinstock, Chana...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669093/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

FDA Approval Summary: Tivozanib for Relapsed or Refractory ..:

Chang, Elaine ; Weinstock, Chana ; Zhang, Lijun...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810577/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
12

FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for t..:

Narayan, Preeti ; Osgood, Christy L ; Singh, Harpreet...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570919/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
13

Successes and Challenges of PARP Inhibitors in Cancer Thera..:

Ricks, Tiffany K ; Chiu, Haw-Jyh ; Ison, Gwynn...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604313/.  , 2015
Link: http://www.ncbi.nlm.nih...
 
?
14

Immunoglobulin E plays an immunoregulatory role in lupus:

Dema, Barbara ; Charles, Nicolas ; Pellefigues, Christophe...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203948/.  , 2014
Link: http://www.ncbi.nlm.nih...
 
?
15

Autoreactive IgE Is Prevalent in Systemic Lupus Erythematos..:

Dema, Barbara ; Pellefigues, Christophe ; Hasni, Sarfaraz...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938730.  , 2014
Link: http://www.ncbi.nlm.nih...
 
1-15